SaifM. MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer. JOP. Journal of the Pancreas, v. 15, n. 3, p. 278-279, 27 maio 2014.